[go: up one dir, main page]

EA201691866A1 - Проникающие в опухоль лимфоциты для адоптивной клеточной терапии - Google Patents

Проникающие в опухоль лимфоциты для адоптивной клеточной терапии

Info

Publication number
EA201691866A1
EA201691866A1 EA201691866A EA201691866A EA201691866A1 EA 201691866 A1 EA201691866 A1 EA 201691866A1 EA 201691866 A EA201691866 A EA 201691866A EA 201691866 A EA201691866 A EA 201691866A EA 201691866 A1 EA201691866 A1 EA 201691866A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell therapy
lymphocytes
permitting
tumor
methods
Prior art date
Application number
EA201691866A
Other languages
English (en)
Other versions
EA036386B1 (ru
Inventor
Амод А. Сарнейк
Шари Пайлон-Томас
Марк Маклафлин
Хао ЛЮ
Original Assignee
Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк.
Юнивёрсити Оф Саус Флорида
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк., Юнивёрсити Оф Саус Флорида filed Critical Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк.
Publication of EA201691866A1 publication Critical patent/EA201691866A1/ru
Publication of EA036386B1 publication Critical patent/EA036386B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)

Abstract

В заявке описываются композиции и способы наращивания проникающих в опухоль лимфоцитов ex vivo с целью их применения при адоптивной клеточной терапии (АКТ). Также описываются композиции и способы идентификации агента для наращивания проникающих в опухоль лимфоцитов ex vivo с целью их применения при АКТ. Также в изобретении предлагаются способы лечения рака с применением проникающих в опухоль лимфоцитов, нарощенных с помощью описанных в настоящем документе способов.
EA201691866A 2014-03-20 2015-03-20 Проникающие в опухоль лимфоциты для адоптивной клеточной терапии EA036386B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955970P 2014-03-20 2014-03-20
US201461973002P 2014-03-31 2014-03-31
PCT/US2015/021759 WO2015143328A1 (en) 2014-03-20 2015-03-20 Tumor-infiltrating lymphocytes for adoptive cell therapy

Publications (2)

Publication Number Publication Date
EA201691866A1 true EA201691866A1 (ru) 2017-01-30
EA036386B1 EA036386B1 (ru) 2020-11-03

Family

ID=54145388

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691866A EA036386B1 (ru) 2014-03-20 2015-03-20 Проникающие в опухоль лимфоциты для адоптивной клеточной терапии

Country Status (11)

Country Link
US (3) US20170081635A1 (ru)
EP (2) EP3698850A1 (ru)
JP (4) JP2017511375A (ru)
KR (3) KR20160146713A (ru)
CN (2) CN112080467A (ru)
AU (3) AU2015231041B2 (ru)
CA (1) CA2943389C (ru)
EA (1) EA036386B1 (ru)
ES (1) ES2776407T3 (ru)
MX (2) MX374472B (ru)
WO (1) WO2015143328A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015231041B2 (en) 2014-03-20 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
EP3228701A1 (en) * 2016-04-05 2017-10-11 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
MX2019000149A (es) 2016-07-07 2019-09-23 Iovance Biotherapeutics Inc Proteinas de union a ligando 1 de muerte programada 1 (pd-l1) y metodos de uso de las mismas.
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA46916A (fr) 2016-11-17 2019-09-25 Iovance Biotherapeutics Inc Resttumorinfiltrierende lymphozyten und verfahren zur herstellung und verwendung davon
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JP2020509018A (ja) * 2017-03-01 2020-03-26 ネクター セラピューティクス 養子細胞移植療法と併せてインターロイキン−２受容体α，β−選択的作動薬を用いる免疫療法的治療方法
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
KR20200010468A (ko) 2017-05-24 2020-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
WO2018226714A1 (en) * 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
CN111836887A (zh) 2018-01-08 2020-10-27 艾欧凡斯生物治疗公司 产生富含肿瘤抗原特异性t细胞的til产品的方法
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
KR20210005138A (ko) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도
CN108486120B (zh) * 2018-04-28 2019-12-06 新乡医学院 一种新型CpG ODN序列及其在抗黑色素瘤上的应用
US20220090018A1 (en) 2018-11-05 2022-03-24 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and used of the same in immunotherapy
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
BR112022021020A2 (pt) 2020-04-22 2023-02-14 Iovance Biotherapeutics Inc Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular
JP2023524435A (ja) 2020-04-28 2023-06-12 アキレス セラピューティクス ユーケー リミテッド Ｔ細胞療法
CA3196553A1 (en) * 2020-10-27 2022-05-05 Amer BEG Oncolytic virus boosts t cell response for effective til therapy
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
IL309200A (en) 2021-06-22 2024-02-01 Achilles Therapeutics Uk Ltd A method for producing antigen-specific t cells
US20230270784A1 (en) * 2021-12-07 2023-08-31 Memgen, Inc. Oncolytic virus boosts t cell response for effective til therapy
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU2004287884C1 (en) 2003-11-05 2012-11-29 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US7858743B2 (en) * 2004-09-09 2010-12-28 Ludwig Institute For Cancer Research SSX-4 peptides presented by HLA class II molecules
ATE484578T1 (de) * 2005-08-05 2010-10-15 Helmholtz Zentrum Muenchen Erzeugung allorestriktiver spezifischer t-zellen
US8211425B2 (en) * 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
CA2704232C (en) 2007-11-08 2017-05-02 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
JP5816627B2 (ja) * 2009-10-27 2015-11-18 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
WO2013192628A1 (en) 2012-06-22 2013-12-27 University Of South Florida Peptoid-peptide hybrids and their use
CN103243072B (zh) * 2013-05-09 2016-03-02 杭州中赢生物医疗科技有限公司 CD8α-白介素21片段-CD137复合物扩增激活淋巴细胞的方法
CN103396992A (zh) * 2013-08-15 2013-11-20 中国人民解放军第二军医大学 寡克隆肝癌肿瘤浸润淋巴细胞的培养和应用
CN103520198B (zh) * 2013-09-24 2016-01-20 彭光勇 一种制备用于阻止肿瘤细胞诱导t细胞老化并逆转其免疫抑制能力的药物的方法及其在抗肿瘤免疫治疗中的用途
AU2015231041B2 (en) 2014-03-20 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy

Also Published As

Publication number Publication date
EP3119477A4 (en) 2018-03-07
EP3119477A1 (en) 2017-01-25
CA2943389C (en) 2023-10-31
EP3698850A1 (en) 2020-08-26
AU2015231041B2 (en) 2020-07-16
AU2015231041A1 (en) 2016-11-03
KR20250004905A (ko) 2025-01-08
JP2023123877A (ja) 2023-09-05
CN106659913A (zh) 2017-05-10
JP2017511375A (ja) 2017-04-20
MX374472B (es) 2025-03-06
US20220282215A1 (en) 2022-09-08
EA036386B1 (ru) 2020-11-03
AU2023200308A1 (en) 2023-03-02
US12291724B2 (en) 2025-05-06
US11518980B2 (en) 2022-12-06
AU2020256412A1 (en) 2020-11-26
KR20230085225A (ko) 2023-06-13
ES2776407T3 (es) 2020-07-30
JP2025041755A (ja) 2025-03-26
EP3119477B1 (en) 2020-01-01
NZ762786A (en) 2024-05-31
US20190177693A1 (en) 2019-06-13
MX2020005634A (es) 2020-08-20
BR112016021370A2 (pt) 2017-08-15
WO2015143328A1 (en) 2015-09-24
US20170081635A1 (en) 2017-03-23
CA2943389A1 (en) 2015-09-24
MX2016012176A (es) 2017-04-13
KR20160146713A (ko) 2016-12-21
JP2020182477A (ja) 2020-11-12
CN112080467A (zh) 2020-12-15
BR112016021370A8 (pt) 2021-07-20

Similar Documents

Publication Publication Date Title
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
PH12020551923A1 (en) Methods and compositions for treating cancer
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
NZ731467A (en) Anti-tim3 antibodies and methods of use
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
GB2557123A (en) Modified cells and methods of therapy
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201300171A1 (ru) Способы и композиции для терапии рака печени
EA201790913A1 (ru) Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
EP4527922A3 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
EA201590987A1 (ru) Соединения и способы их применения
MX387283B (es) Tratamiento del cancer con tg02.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
NZ776616A (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra